1. Home
  2. TVTX vs CASH Comparison

TVTX vs CASH Comparison

Compare TVTX & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • CASH
  • Stock Information
  • Founded
  • TVTX 2008
  • CASH 1954
  • Country
  • TVTX United States
  • CASH United States
  • Employees
  • TVTX N/A
  • CASH N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • CASH Major Banks
  • Sector
  • TVTX Health Care
  • CASH Finance
  • Exchange
  • TVTX Nasdaq
  • CASH Nasdaq
  • Market Cap
  • TVTX 1.5B
  • CASH 1.7B
  • IPO Year
  • TVTX N/A
  • CASH N/A
  • Fundamental
  • Price
  • TVTX $24.64
  • CASH $73.66
  • Analyst Decision
  • TVTX Strong Buy
  • CASH Buy
  • Analyst Count
  • TVTX 16
  • CASH 2
  • Target Price
  • TVTX $35.20
  • CASH $91.00
  • AVG Volume (30 Days)
  • TVTX 2.7M
  • CASH 192.8K
  • Earning Date
  • TVTX 10-30-2025
  • CASH 10-22-2025
  • Dividend Yield
  • TVTX N/A
  • CASH 0.27%
  • EPS Growth
  • TVTX N/A
  • CASH N/A
  • EPS
  • TVTX N/A
  • CASH 6.88
  • Revenue
  • TVTX $333,865,000.00
  • CASH $732,567,000.00
  • Revenue This Year
  • TVTX $83.87
  • CASH $18.96
  • Revenue Next Year
  • TVTX $40.99
  • CASH $5.11
  • P/E Ratio
  • TVTX N/A
  • CASH $10.78
  • Revenue Growth
  • TVTX 87.94
  • CASH 1.70
  • 52 Week Low
  • TVTX $12.91
  • CASH $62.79
  • 52 Week High
  • TVTX $28.69
  • CASH $86.00
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 59.38
  • CASH 38.77
  • Support Level
  • TVTX $23.22
  • CASH $72.76
  • Resistance Level
  • TVTX $25.10
  • CASH $76.18
  • Average True Range (ATR)
  • TVTX 1.27
  • CASH 1.97
  • MACD
  • TVTX -0.23
  • CASH -0.23
  • Stochastic Oscillator
  • TVTX 63.75
  • CASH 11.42

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: